Patients with idiopathic pulmonary fibrosis-associated chronic cough who received twice-daily oral extended release nalbuphine for 6 weeks had decreases in 24-hour cough frequency, according to data ...

A new study published in the Journal of the American Medical Association showed that all three doses of extended-release ...

Trevi Therapeutics, Inc. (NASDAQ:TRVI) revealed topline results on Monday from its Phase 2b CORAL trial of Haduvio for chronic cough in patients with idiopathic pulmonary fibrosis (IPF) (N=165). The ...

Duloxetine is significantly more effective than placebo at reducing refractory chronic cough (RCC) frequency and sensitivity.

Once you understand what's behind your cough, choosing the right treatment becomes much easier.

Opioid agonist/antagonist has a big impact in phase IIb trial ...

On Monday, Trevi Therapeutics, Inc. (NASDAQ:TRVI) reported topline results from its Phase 2a RIVER trial of Haduvio (oral nalbuphine ER) for the treatment of patients with refractory chronic cough ...

Camlipixant showed significant efficacy in patients with higher baseline cough frequency, despite not meeting the primary endpoint in the overall population. The trial demonstrated camlipixant's ...

So, you have a cough. Experts say this is when to see a doctor - While many coughs are often the result of viral infections, ...

When it comes to respiratory health, a cough serves as the body’s primary alert system, protecting airways from harmful substances and clearing unwanted material. Yet for millions of Americans, this ...

Coughing is one of the body’s most essential protective reflexes, designed to remove foreign irritants like dust, bacteria, and viruses from the airways. While it serves a critical role in keeping us ...